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Summary During the interval 1968-74, 17,032 women aged 25-39 years were recruited to the Oxford-Family
Planning Association contraceptive study, more than half of whom were using oral contraceptives. These
women have been followed up over the years and breast cancer has been diagnosed in 189 of them We have
analysed the available data in two ways. First, we have calculated standardised breast cancer incidence rates
in non-users and users of oral contraceptives according to total duration of use, interval since first use,
interval since last use, duration of use before first term pregnancy and duration of use before age 25.
Secondly, we have conducted case-control within cohort analyses to examine the possible effects of different
types of pill and to search for evidence of a latent effect of oral contraceptive use before first term pregnancy
on breast cancer risk. We have found no evidence of any adverse effect of oral contraceptive use on the risk
of breast cancer in this study. There was, however, little exposure to the pill before first term pregnancy
among the participants and virtually no such exposure at a very young age (i.e. below 20 years). Accordingly,
the results of this study strengthen the evidence that oral contraceptive use by mature women does not
increase breast cancer risk, but add little to the uncertainty about the effects of early use.
A large number of case-control studies of the relationship
between oral contraceptives and breast cancer have been
published (see McPherson et al., 1987; Vessey, 1987).
Considered together, these studies provide strong evidence
that the use of oral contraceptives in the middle of the fertile
years (say, between the ages of 25 and 39 years) has no
adverse effect on breast cancer risk. There remains, however,
considerable anxiety about the effects of oral contraceptive
use at an early age, especially before first term pregnancy;
thus some studies have yielded reassuring findings about
such exposure (Vessey et al., 1982; Stadel et al., 1985; Paul et
al., 1986) while others have not (Pike et al., 1983; Meirik et
al., 1986; McPherson et al., 1987).
Not surprisingly, few data are available from cohort
studies about oral contraceptive use and breast cancer. We
last reported on this topic from the Oxford-Family Planning
Association (Oxford-FPA) cohort study in 1981 when 72
incident cases of breast cancer had occurred (Vessey et al.,
1981). We now present our latest findings, based on 189
incident cancers.
Methods
A detailed description of the methods used in the Oxford-
FPA study has been given elsewhere (Vessey et al., 1976). In
brief, 17,032 women were recruited at 17 large family
planning clinics in England and Scotland during 1968-74. At
the time of recruitment, each of these women had to be (i)
aged 25-39 years, (ii) married, (iii) a white British subject,
(iv) willing to participate and (v) either a current user of oral
contraceptives with at least 5 months' use or a current user
of a diaphragm or an intrauterine device with at least 5
months' use without previous exposure to the pill. During
follow-up, each women is questioned at return visits to the
clinic by a doctor or nurse and certain items of information
are recorded on a special form, including details of
pregnancies and their outcome, changes in contraceptive
practices and reasons for referral to hospital. Women who
stop attending the clinic are sent a postal version of the
questionnaire and, if this is not returned, are interviewed on
the telephone or at a home visit. Each hospital admission is
followed up by writing to the consultant concerned and a
copy of the relevant discharge summary is obtained (with
histological details if appropriate). The work in each clinic is
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co-ordinated by a part-time research assistant and follow-up
has been maintained with an annual loss rate because of
withdrawal of co-operation or loss of contact of only about
0.3%. The records of all the participants are 'labelled' in the
National Health Service Central Registries in Southport and
Edinburgh, leading to automatic notification of deaths and
of a substantial proportion of cancer registrations (see
Villard-Mackintosh et al., 1988).
When women reach the age of 45 years, they are divided
into three groups: (i) those who have never used the pill; (ii)
those with 8 or more years use of the pill; and (iii) the
remainder. Only the women in the first two of these groups
are subsequently followed up intensively in the way
described above. The women in the third group (of whom
there were 2,879 on 1 September 1987) are followed up only
by means of the National Health Service Central Registries.
For these reasons, data for women aged 45 years or more
are shown separately in the analyses which follow; women in
the third group are excluded because the ascertainment of
breast cancer among them is known to be incomplete
(Villard-Mackintosh et al., 1988). The results presented here
thus concern 189 women with histologically proven cancer of
the breast first diagnosed during follow-up before 1
September 1987.
The first part of the analysis (the cohort analysis) is based
on the computation of woman-years of observation in the
contraceptive groups compared; incidence rates are
standardised by the indirect method as described by Vessey
et al. (1976). The influence of a wide range of potentially
confounding variables was investigated including age, parity,
age at first term pregnancy, age at natural or artificial
menopause, type of artificial menopause (hysterectomy with
retention of one or more ovaries, removal of both ovaries
with or without hysterectomy), social class, weight, height,
Quetelets index and history of hospital referral for benign
breast disease. Social class and measures of body size
showed no important relationship with breast cancer risk in
this study. Of the other variables, age had by far the most
important confounding effect, but we also took the influence
of parity and age at first term pregnancy into account in the
analyses concerning women aged up to 44 years, and these
variables plus age at menopause and type of menopause into
account in the analyses concerning the older women. The
inclusion of a history of hospital referral for benign breast
disease in the adjustment procedure had only a trivial effect
on the results. In view of the uncertainty as to whether or
not it is appropriate to adjust for this variable in analyses
pertaining to oral contraceptive use (see Stadel &
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Schlesselman, 1986), we decided to omit it in the tables
presented here.
The second part of the analysis, which is concerned with
pill brand and with a search for a latent effect following oral
contraceptive use before first term pregnancy, utilises case-
control methodology. We have found that this approach is
much simpler to use than the cohort approach when
studying highly complex relationships. In this analysis, each
woman with breast cancer was first matched with two other
women without the disease. Each of these controls had to
match the corresponding case with respect to age (same 2
year group), clinic of recruitment and date of recruitment
(same 6 month group). In addition, each control had to be
under active follow-up in the study at the time the case was
diagnosed as having breast cancer. This set of cases and
controls was used to investigate the possible importance of
pill brand overall. The matching procedure was then
repeated, limiting attention to women up to 44 years of age,
introducing additional matching for age at first term
pregnancy (nulliparous, 20, 21, 22, 23,..., 34, 35+), and
omitting (of necessity) matching for clinic of recruitment.
This set of cases and controls was used to investigate the
possible importance of pill brand before first term pregnancy
and to search for evidence of a latent effect following such
early use (see McPherson et al., 1987).
Results
Cohort analysis
Table I shows data on the risk of breast cancer in relation to
total duration of oral contraceptive use and age. Although
the rates are adjusted for a number of potentially
confounding variables, only age (as previously stated) had an
important influence on the figures. At ages up to 44 years,
there was no relationship between total duration of oral
contraceptive use and breast cancer. The same was true
when the figures were examined within 5 year age groups
(data not shown), but only 14 women in the study developed
breast cancer below the age of 35 years (all the women are,
of course, now over that age). At age 45 years or more there
was a negative association between total duration of oral
contraceptive use and breast cancer, but this did not reach
statistical significance.
The relationship between breast cancer risk and interval
since oral contraceptives were first used is examined in Table
II. As before, age was the only important confounding
variable. In the younger age group (and in 5 year subgroups
within it), there was no suggestion of any association.
Among women aged 45 years or more, the rates were
significantly heterogeneous, mainly because of a deficiency of
cancers in the longest interval group. We have been unable
to find any explanation for this observation, and the matter
will be kept under review as more data accumulate.
Table III deals with the association between breast cancer
risk and the interval since oral contraceptives were last used.
Again, there is no relationship in the younger age group,
while there is a (non-significant) negative association in the
older age group.
The data in Tables I-III are reassuring, but on the basis
of published work (both our own and that of others) we
expected them to be so. Table IV examines the much more
contentious issue of the effect of early oral contraceptive use.
The analysis is limited to women under the age of 45 years,
because early oral contraceptive use was very rare in the
older women. While the data provide no evidence of an
adverse effect of early oral contraceptive use (either before
first term pregnancy or before age 25), the small numbers of
observations in the key cells prevent an adequate test of the
hypothesis that such exposure might be harmful.
Furthermore, it is important to note the pattern of 'early'
oral contraceptive use in our cohort. Thus virtually none of
the exposure occurred before the age of 20 years (a total of
only 15 woman-years among the 17,032 participants in the
study).
Table I Breast cancer incidence by total duration of oral contraceptive use and age
Ages 25-44 Ages >45
Total duration of
oral contraceptive Number of Rate per 1,000 Number of Rate per 1,000
use (months) cases woman-years cases woman-years
Never used 49 0.62 50 2.24
<23 9 0.56 - -
24-47 11 0.50
48-71 16 0.61
72-95 15 0.64 -
96-119 12 0.65 5 1.58
>120 14 0.65 8 1.08
Adjusted for age (2 year groups), parity (0, 1-2, >3 births), age at first term
pregnancy (no pregnancy, < 19, 20-24, >25 years) and, for those aged >45, age and
type of menopause (still menstruating; natural menopause at age <40, 40-44, >45;
hysterectomy with at least one ovary retained at age <40, 40-44, >45; bilateral
oophorectomy with or without hysterectomy at age <40, 40-44, >45). Age at first
term pregnancy was unknown in two clinics, so age at marriage plus one year was
substituted. Ages 25-44 years, X =0.69 (n.s.). Ages >45 years, X'=4.11 (n.s.).
Table II Breast cancer incidence by interval since first oral contraceptive use and age
Ages 25-44 Ages >45
Interval since first
oral contraceptive Number of Rate per 1,000 Number of Rate per 1,000
use (months) cases woman-years cases woman-years
Never used 49 0.62 50 2.24
<47 7 0.71 - _
48-95 13 0.52
96-143 20 0.57 -
144-191 22 0.63 7 2.71
> 192 15 0.66 6 0.80
Adjustments as for Table I. Ages 25-44 years, X2=0.71 (n.s.). Ages >45 years,
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Table III Breast cancer incidence by interval since last oral contraceptive use and
age
Ages 25-44 Ages >45
Interval since last
oral contraceptive Number of Rate per 1,000 Number of Rate per 1,000
use (months) cases woman-years cases woman-years
Never used 49 0.62 50 2.24
Current user 24 0.67)
<23 17 0.86 7 1.80
24-47 9 0.50 J
48-71 6 0.35
72-95 10 0.68 6 0.90
96-119 4 0.39
,120 7 0.61 )
Adjustments as for Table I. Ages 25-44 years, x2=5.4 (n.s.). Ages >r45 years,
X2=4.8 (n.s.).
Table IV Breast cancer incidence by use of oral contraceptives before first term
pregnancy and use of oral contraceptives before age 25 years (women aged up to 44
years only)
Use before first
term pregnancy Use before age 25 years
Total duration of
oral contraceptive Number of Rate per 1,000 Number of Rate per 1,000
use (months) cases woman-years cases woman-years
Never used 84 0.57 108 0.62
<47 15 0.83 17 0.57
>48 7 0.62 1 0.75
Adjustments as for Table I. The data for the two clinics for which age at first term
pregnancy was unknown have been omitted from the left hand part of the table,
reducing the number of cancers from 126 to 106. Use before first term pregnancy,
=1.80 (n.s.). Use before age 25 years, X2 =0.12 (n.s.).
Table V Types of oral contraceptive used at any time by 189 women with breast cancer and 378 matched controls
and before first term pregnancy by 103 women up to 44 years of age with breast cancer and 206 matched controlsa
OC use at any time OC use beforefirst term pregnancy
Cases Controls Cases Controls
Total Total Total Total
No. of months No. of months No. of months No. of months
OCs used users used users used users used users used
Oestrogen type and dose in pill
Ethinyl-oestradiol 100jig 6 56 14 187 1 15 1 17
50jg 70 3,828 155 8,872 16 586 29 991
30jug 33 792 64 1,528 3 28 3 37
Any dose 81 4,762 177 10,659 17 629 29 1,045
Mestranol 100pg 21 625 42 1,524 4 96 2 44
50,g 33 1,707 76 3,351 6 126 15 263
Any dose 55 2,902 128 6,092 11 263 21 411
Progestogen type in pill
Norethisterone acetate 42 2,125 102 3,968 10 306 14 395
Norethisterone 42 2,182 96 4,528 6 129 15 266
Lynoestrenol 28 1,078 67 2,948 5 182 17 478
Megestrol acetate 14 454 38 1,310 2 57 10 171
Ethynodiol diacetate 22 912 47 2,744 6 154 4 85
Norgestrel/Levonorgestrel 40 1,044 73 1,945 4 67 3 56
Major individual pillsb
Anovlar 8 254 8 249 1 22 1 4
Gynovlar 19 765 52 1,892 3 82 8 299
Lyndiol 2.5 14 279 31 681 3 41 8 101
Minovlar 22 814 53 1,412 7 202 6 74
Norinyl-l 27 1,300 53 2,406 5 120 11 212
Norlestrin 4 290 12 394 0 0 2 18
Ovulen 14 391 34 1,176 4 96 2 39
Ovulen 50 11 344 27 1,334 3 58 2 37
Volidan 10 398 29 1,082 2 42 9 154
Orthonovin 1/50 12 407 33 945 1 6 4 51
Minilyn 23 759 53 2,165 4 141 15 373
Eugynon 30 16 386 37 744 0 0 0 0
aOmitting data for two clinics at which age at first term birth unknown and three cases who could not be matched;
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Table VI Relative risks (95% confidence intervals) of breast cancer associated with oral contraceptive use
before first term pregnancy after excluding all such use within the stated period before diagnosis (or
equivalent date for the controls)
Exclusion Months use Oral contraceptives
period before first All oral containing Oral contraceptives
(years) term pregnancy contraceptives ethinyl-oestradiol containing mestranol
0 Never 1.00 1.00 1.00
1-12 0.48 (0.05- 4.21) 0.87 (0.15- 4.94) 0.65 (0.17- 2.45)
13-47 1.66 (0.44- 6.26) 1.21 (0.28- 5.28) 0.98 (0.31- 3.07)
>48 1.18 (0.28- 4.93) 1.03 (0.23- 4.53) 1.61 (0.09-29.07)
6 Never 1.00 1.00 1.00
1-12 0.46 (0.09- 2.50) 1.10 (0.20- 5.93) 0.09 (0.17- 2.30)
13-47 1.40 (0.33- 5.92) 0.83 (0.14- 4.95) 1.54 (0.41- 5.77)
>48 1.03 (0.23- 4.64) 0.63 (0.13- 3.05) 1.60 (0.09-28.90)
10 Never 1.00 1.00 1.00
1-12 0.72 (0.07- 7.04) 0.50 (0.05- 5.06) 0.53 (0.12- 2.42)
13-47 2.44 (0.59-10.00) 2.36 (0.35-16.11) 1.50 (0.40- 5.60)
>48 0.87 (0.19- 3.97) 0.60 (0.10- 3.43) 1.58 (0.09-28.20)
Case-control analysis
For this part of the analysis, we had two sets of data. One
concerned all 189 women with breast cancer and 378
controls matched for age, clinic and date of recruitment. The
second concerned 103 of the 126 women with breast cancer
aged up to 44 years and 206 controls matched for age, date
of recruitment and age at first pregnancy. We first confirmed
the general findings in the cohort analyses already described
above. We then turned our attention to a detailed assessment
of possible variation in the effects of different types of pill.
Table V illustrates the main results. Data are given
separately for lifetime use of oral contraceptives (based on
all 189 cases) and for use before first term pregnancy (based
on 103 cases). The figures shown are obviously difflcult to
assess. However, in the absence of an effect, the ratio of
months used in the cases to months used in the controls in
any category would be expected to be 0.5. If, entirely
arbitrarily, we regard preparations showing a ratio greater
than 0.7 or less than 0.3 as 'outliers', then the only ones to
fall in this category in the overall analysis are Anovlar (ratio
1.02) and Ovulen 50 (ratio 0.26). The data for oral contra-
ceptive use before first term pregnancy are even more
difficult to assess because there is little such exposure.
However, if we apply the same test criteria as before and, in
addition, require there to be at least 100 woman-years of
exposure in the controls, then the 'outliers' are norethi-
sterone acetate (ratio 0.78), Gynovlar (ratio 0.27) and
Volidan (ratio 0.27). All.in all, although there obviously is
variation in exposure to different steroids and individual pills
among the cases and controls, we have been unable to
discern any clear patterns, either in the data shown in Table
V or in other analyses not reproduced here.
Finally, we used the second set of case-control data to
investigate a possible latent effect of oral contraceptive use
before first term pregnancy. To do this, we excluded
successively oral contraceptive use before first term
pregnancy within 2, 4,..., 10 years of diagnosis (or the
equivalent date for the controls). Estimated relative risks of
breast cancer associated with particular durations of oral
contraceptive use before first term pregnancy would be
expected to change in such an analysis if there was a delayed
effect of exposure. The analysis, in fact, showed no trends in
relative risk estimate; this was true both for the overall data
and for analyses categorised by the type of oestrogen
contained in the oral contraceptives used. The data were,
however, extremely sparse. Representative findings are given
in Table VI.
Discussion
The findings in studies of oral contraceptive use and breast
cancer have recently been reviewed in detail elsewhere
(McPherson et al., 1987; Vessey, 1987) and the interested
reader is referred to these reviews. In brief, as we stated
earlier, there is a consensus that the use of oral contra-
ceptives by women in the middle of the fertile years (say
between 25 and 39 years) has no adverse effect on breast
cancer risk and our findings add weight to this conclusion.
There is, on the other hand, continuing anxiety about the
effects of oral contraceptive use at an early age, especially
before first term pregnancy. Furthermore, McPherson et al.
(1987) suggested that any adverse effect might particularly be
associated with oral contraceptives containing ethinyl-
oestradiol (rather than mestranol) and might be enhanced
with the passage of time from exposure. Schlesselman et al.
(1987, 1988) found no evidence to support these suggestions
in the Cancer & Steroid Hormones Study, and likewise, the
findings we have presented here are essentially negative. It
should be stressed, however, that our data are extremely
sparse and that virtually no exposure occurred in the cohort
at ages younger than 20 years. Research must continue into
the important question of the possible relationship between
oral contraceptive use and breast cancer, especially early use.
We thank Mrs C. Brice, Mrs P. Brown, Mrs D. Collinge and the
research assistants, doctors, nurses and administrative staff working
at the participating clinics for their hard work and loyal support.
We are also grateful to the Medical Research Council for financial
assistance.
Appendix
Oestrogen and progestogen content of oral contraceptives
referred to in text and Table V
Oestrogen (Mg) Progestogen (mg)
Anovlar 50EO 4.0NA
Gynovlar 50EO 3.0NA





Ovulen 50 50EO 1.0EDD
Volidan 50EO 4.0MA
Orthonovin 1/50 50M 1.0N
Minilyn 50EO 2.5 LE
Eugynon 30 30EO 0.25LN
Oestrogens: EO, Ethinyloestradiol; M, Mestranol.
Progestogens: NA, Norethisterone acetate; LE,
Lynoestrenol; N, Norethisterone; EDD, Ethynodiol
diacetate; MA, Megestrol acetate; LN, Levonorgestrel.ORAL CONTRACEPTIVES AND BREAST CANCER 617
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